MP
TNGX icon

Mangrove Partners’s Tango Therapeutics TNGX Stock Holding History

Mangrove Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,557
Closed -$263K – 581
2026
Q1 		$263K Buy
+12,557
New +$175K 0.02% 281

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Mangrove Partners's TNGX Position: Q2 2026 in Review

Mangrove Partners sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 12,557 shares — an estimated $263K sold.

Mangrove Partners first reported a position in TNGX in Q1 2026 and held it in 1 quarter. The position peaked at $263K in Q1 2026. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Mangrove Partners reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mangrove Partners sold 12,557 Tango Therapeutics shares in Q2 2026, an estimated $263K.
  • Mangrove Partners first reported a position in Tango Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mangrove Partners's Tango Therapeutics position peaked at $263K in Q1 2026.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.